|
|
|||||||||||||||||||||||||||
|
Flexion Therapeutics, Inc. (FLXN) Flexion Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. Co.'s product, ZILRETTA®, is an injection indicated for the management of OA knee pain. Co. has two product candidates focused on the treatment of musculoskeletal conditions: FX201 and FX301. FX201, is a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist. FX301, is a NaV1.7 inhibitor formulated for extended release in a thermosensitive hydrogel.
|
|
|||||||||||||||||||||||||||
Free FLXN Email Alerts:
Flexion Therapeutics, Inc. (FLXN) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.